| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,283 | -2,124 |
| Depreciation | 0 | 0 |
| Change in fair value of warrant liability | 31 | 31 |
| Common stock issued for services rendered | 174 | - |
| Stock-based compensation | 379 | 252 |
| Receivables | -5 | -3 |
| Prepaid expenses and other current assets | -148 | 18 |
| Accounts payable | 327 | 293 |
| Accrued expenses | -98 | 90 |
| Net cash flows from operating activities | -2,317 | -1,473 |
| Purchases of property and equipment | 97 | - |
| Net cash flows from investing activities | -97 | - |
| Proceeds from the issuance of common stock and pre funded warrants, net of offering costs | 1,911 | 1,911 |
| Proceeds from sale of series a-1 preferred stock | 500 | 500 |
| Proceeds from sale of series a-2 preferred stock | 850 | 850 |
| Net cash flows from financing activities | 3,261 | 3,261 |
| Net increase (decrease) in cash, cash equivalents | 847 | 1,788 |
| Cash and cash equivalents at beginning of period | 1,091 | - |
| Cash and cash equivalents at end of period | 1,938 | - |
Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. (TCRT)